Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Serum periostin levels in asthma patients in relation to omalizumab therapy and presence of chronic rhinosinusitis with nasal polyps

J. Novosad, I. Krčmová, V. Bartoš, M. Drahošová, P. Vaník, O. Růžičková-Kirchnerová, M. Teřl, J. Krejsek,

. 2020 ; 37 (2) : 240-249. [pub] 20200506

Jazyk angličtina Země Polsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20019401

Introduction: The serum periostin level is a promising biomarker of type 2- high inflammation pattern of bronchial asthma. It has been proven that serum periostin levels decrease in response to systemic and inhaled corticosteroid (ICS) therapy. However, we have only limited knowledge about changes in serum periostin levels reflecting omalizumab (OMA) treatment and other variables, such as chronic rhinosinusitis with nasal polyps (CRSwNP). Aim: To critically appraise clinically relevant parameters influencing periostin levels in asthma patients. Material and methods: A pilot, cross-sectional, observational study to assess serum periostin levels of 48 asthma patients (38 treated by conventional therapy comprising ICS and 10 treated by ICS and OMA as an add-on therapy) with respect to asthma clinical traits, comorbidities and to other biomarkers of type 2-high asthma phenotype (total IgE, absolute and relative eosinophil count, eosinophilic cationic protein (ECP) and a fraction of exhaled NO (FeNO)). Results: Serum periostin correlates with total IgE levels (Spearman rho = 0.364, p = 0.025) in a subgroup of conventionally treated patients, and with eosinophil count (Spearman rho = 0.401, p = 0.021) in a subgroup of patients with concurrent CRSwNP. Serum periostin levels were decreased in omalizumab-treated patients in comparison to conventionally treated patients (p = 0.025). This effect was remarkably apparent only if CRSwNP was not present (p = 0.005). Conversely, we measured elevated periostin levels in OMA-treated patients with concurrent CRSwNP (p = 0.017). Conclusions: Serum periostin production is significantly associated with treatment modality (omalizumab vs. conventional) and presence of CRSwNP. These variables need to be taken into account to interpret periostin levels accurately.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20019401
003      
CZ-PrNML
005      
20201123123350.0
007      
ta
008      
201103s2020 pl f 000 0|eng||
009      
AR
024    7_
$a 10.5114/ada.2020.94842 $2 doi
035    __
$a (PubMed)32489361
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Novosad, Jakub $u Institute of Clinical Immunology and Allergy, University Hospital in Hradec Králové, Faculty of Medicine, Charles University in Prague, Czech Republic.
245    10
$a Serum periostin levels in asthma patients in relation to omalizumab therapy and presence of chronic rhinosinusitis with nasal polyps / $c J. Novosad, I. Krčmová, V. Bartoš, M. Drahošová, P. Vaník, O. Růžičková-Kirchnerová, M. Teřl, J. Krejsek,
520    9_
$a Introduction: The serum periostin level is a promising biomarker of type 2- high inflammation pattern of bronchial asthma. It has been proven that serum periostin levels decrease in response to systemic and inhaled corticosteroid (ICS) therapy. However, we have only limited knowledge about changes in serum periostin levels reflecting omalizumab (OMA) treatment and other variables, such as chronic rhinosinusitis with nasal polyps (CRSwNP). Aim: To critically appraise clinically relevant parameters influencing periostin levels in asthma patients. Material and methods: A pilot, cross-sectional, observational study to assess serum periostin levels of 48 asthma patients (38 treated by conventional therapy comprising ICS and 10 treated by ICS and OMA as an add-on therapy) with respect to asthma clinical traits, comorbidities and to other biomarkers of type 2-high asthma phenotype (total IgE, absolute and relative eosinophil count, eosinophilic cationic protein (ECP) and a fraction of exhaled NO (FeNO)). Results: Serum periostin correlates with total IgE levels (Spearman rho = 0.364, p = 0.025) in a subgroup of conventionally treated patients, and with eosinophil count (Spearman rho = 0.401, p = 0.021) in a subgroup of patients with concurrent CRSwNP. Serum periostin levels were decreased in omalizumab-treated patients in comparison to conventionally treated patients (p = 0.025). This effect was remarkably apparent only if CRSwNP was not present (p = 0.005). Conversely, we measured elevated periostin levels in OMA-treated patients with concurrent CRSwNP (p = 0.017). Conclusions: Serum periostin production is significantly associated with treatment modality (omalizumab vs. conventional) and presence of CRSwNP. These variables need to be taken into account to interpret periostin levels accurately.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Krčmová, Irena $u Institute of Clinical Immunology and Allergy, University Hospital in Hradec Králové, Faculty of Medicine, Charles University in Prague, Czech Republic.
700    1_
$a Bartoš, Vladimír $u Department of Pulmonary Medicine, University Hospital in Hradec Králové, Faculty of Medicine, Charles University in Prague, Czech Republic.
700    1_
$a Drahošová, Marcela $u Institute of Clinical Immunology and Allergy, University Hospital in Hradec Králové, Faculty of Medicine, Charles University in Prague, Czech Republic.
700    1_
$a Vaník, Petr $u Department of Respiratory Diseases, Hospital in České Budějovice, Faculty of Medicine in Pilsen, Charles University in Prague, Czech Republic.
700    1_
$a Růžičková-Kirchnerová, Olga $u Department of Pulmonary Medicine, University Hospital in Pilsen, Faculty of Medicine, Charles University in Prague, Czech Republic.
700    1_
$a Teřl, Milan $u Department of Pulmonary Medicine, University Hospital in Pilsen, Faculty of Medicine, Charles University in Prague, Czech Republic.
700    1_
$a Krejsek, Jan $u Institute of Clinical Immunology and Allergy, University Hospital in Hradec Králové, Faculty of Medicine, Charles University in Prague, Czech Republic.
773    0_
$w MED00172376 $t Postepy dermatologii i alergologii $x 1642-395X $g Roč. 37, č. 2 (2020), s. 240-249
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32489361 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201103 $b ABA008
991    __
$a 20201123123349 $b ABA008
999    __
$a ind $b bmc $g 1586178 $s 1109599
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 37 $c 2 $d 240-249 $e 20200506 $i 1642-395X $m Postępy Dermatologii i Alergologii $n Postepy Dermatol Alergol $x MED00172376
LZP    __
$a Pubmed-20201103

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace